This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
by Urmimala Biswas
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change
earnings-outlook earnings-report healthcare medical medical-devices
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
MASIPositive Net Change FMSPositive Net Change GKOSNegative Net Change GEHCNegative Net Change
medical medical-devices
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
MASIPositive Net Change FMSPositive Net Change GKOSNegative Net Change ITGRNegative Net Change
earnings medical medical-devices
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
BSXNegative Net Change RMDPositive Net Change MMSINegative Net Change EHCPositive Net Change
earnings medical medical-devices
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
by Moumi Mondal
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
BDXNegative Net Change HOLXPositive Net Change GEHCNegative Net Change
earnings-preview medical medical-devices
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
CAHPositive Net Change CORNegative Net Change GMEDNegative Net Change RVTYNegative Net Change
medical medical-devices
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?
AZNPositive Net Change IRTCPositive Net Change SOPHNegative Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices pharmaceuticals
Can Sustained Strength in Water Drive ECL Stock Before Q1 Earnings?
by Zacks Equity Research
Ecolab's first-quarter 2025 results are likely to reflect continued strength in the Water business and strong contribution from the Global Pest Elimination segment.
ECLNegative Net Change BCPCNegative Net Change HWKNPositive Net Change GVDNYPositive Net Change
earnings medical medical-devices
Here's Why You Should Add Veeva Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
MASIPositive Net Change FMSPositive Net Change VEEVNegative Net Change GKOSNegative Net Change
medical medical-devices
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
ABTNegative Net Change BSXNegative Net Change MASIPositive Net Change HIMSPositive Net Change
medical medical-devices
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
MASIPositive Net Change FMSPositive Net Change WSTNegative Net Change GKOSNegative Net Change
earnings medical medical-devices
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
by Zacks Equity Research
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
ANGONegative Net Change MASIPositive Net Change VEEVNegative Net Change PENPositive Net Change
earnings medical medical-devices
Should You Buy Regulus (RGLS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RGLSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
by Zacks Equity Research
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
ANGONegative Net Change EWNegative Net Change MASIPositive Net Change VEEVNegative Net Change
earnings medical medical-devices
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
ISRGNegative Net Change MASIPositive Net Change FMSPositive Net Change GKOSNegative Net Change
earnings medical medical-devices
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
by Zacks Equity Research
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
BSXNegative Net Change ANGONegative Net Change MASIPositive Net Change VEEVNegative Net Change
earnings medical medical-devices
Zacks Investment Ideas feature highlights: SPY, QQQ, MicroStrategy, GameStop and Semler Scientific
by Zacks Equity Research
SPY, QQQ, MicroStrategy, GameStop and Semler Scientific are part of the Zacks Investment Ideas article.
GMEPositive Net Change QQQPositive Net Change SPYNegative Net Change MSTRPositive Net Change SMLRNegative Net Change
computers consumer-discretionary etfs medical-devices
Tesla Q1 Misses on Top & Bottom Lines, Kicks Can on Guidance
by Mark Vickery
Tesla (TSLA) posted its sixth earnings miss in the past seven quarters, coming up -38.6% short.
ISRGNegative Net Change TSLAPositive Net Change
earnings electric-vehicles medical-devices
CVS Soars 53% in Q1: Time to Buy the Stock Ahead of Earnings Release?
by Urmimala Biswas
Caremark, CVS Health's PBM business, is expected to have continued to play a vital role in offsetting the rising cost of branded drugs during the first quarter.
CVSNegative Net Change HLFNegative Net Change WBAPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices retail
Concentra Stock Slips Despite Deal to Acquire Pivot Onsite Innovations
by Zacks Equity Research
CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.
ANGONegative Net Change MASIPositive Net Change VEEVNegative Net Change CONPositive Net Change
medical medical-devices
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
by Zacks Equity Research
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
BDXNegative Net Change CORNegative Net Change LMATNegative Net Change VEEVNegative Net Change
medical medical-devices
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
DGX delivers solid top-line growth in the first quarter of 2025.
ANGONegative Net Change DGXPositive Net Change MASIPositive Net Change VEEVNegative Net Change
earnings medical medical-devices
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
by Moumi Mondal
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
HOLXPositive Net Change MYGNNegative Net Change
medical medical-devices
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
CAHPositive Net Change MMSINegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
ECL Stock Gains Following 5% Trade Surcharge in the United States
by Zacks Equity Research
Ecolab announces a 5% U.S. trade surcharge to offset rising costs.
ECLNegative Net Change ANGONegative Net Change MASIPositive Net Change VEEVNegative Net Change
medical medical-devices